TY  - GEN
AU  - Fowler,Nathan H
AU  - Davis,R Eric
AU  - Rawal,Seema
AU  - Nastoupil,Loretta
AU  - Hagemeister,Fredrick B
AU  - McLaughlin,Peter
AU  - Kwak,Larry W
AU  - Romaguera,Jorge E
AU  - Fanale,Michelle A
AU  - Fayad,Luis E
AU  - Westin,Jason R
AU  - Shah,Jatin
AU  - Orlowski,Robert Z
AU  - Wang,Michael
AU  - Turturro,Francesco
AU  - Oki,Yasuhiro
AU  - Claret,Linda C
AU  - Feng,Lei
AU  - Baladandayuthapani,Veerabhadran
AU  - Muzzafar,Tariq
AU  - Tsai,Kenneth Y
AU  - Samaniego,Felipe
AU  - Neelapu,Sattva S
TI  - Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
SN  - 1474-5488
PY  - 2015///0223
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Lenalidomide
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Rituximab
KW  - Thalidomide
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(14)70455-3
ER  -